

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SUN PHARMACEUTICAL INDUSTRIES, LTD.,
SUN PHARMA GLOBAL FZE and
AMNEAL PHARMACEUTICALS LLC,
Petitioner

v.

ASTRAZENECA AB,
Patent Owner

Case No.: IPR2016-01104
Patent No.: RE44,186

**PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. RE44'186**

Mail Stop PATENT BOARD

Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Submitted Electronically via the Patent Review Processing System

Table of Contents

	<u>Page</u>
I. INTRODUCTION	1
A. Brief Overview of the '186 Patent	2
B. Brief Overview of the Prosecution History	6
C. Brief Overview of the Scope and Content of the Prior Art.....	7
1. The Dipeptide Substrate Targeted By The DP-IV Enzyme.....	7
2. Substituting Hydroxyadamantyl onto the glycyl moiety	9
3. Adding Cyclopropyl to the Pyrrolidine Ring.....	11
D. Overview of Differences Between the Prior Art and the Claims.....	12
E. Level of Skill in the Art.....	13
II. GROUNDS FOR STANDING.....	17
III. MANDATORY NOTICES UNDER 37 C.F.R. § 42.8.....	18
IV. PAYMENT OF FEES UNDER 37 C.F.R. §§ 42.15(A) AND 42.103.....	19
V. STATEMENT OF PRECISE RELIEF FOR EACH CLAIM CHALLENGED	19
VI. CLAIM CONSTRUCTION	21
VII. BACKGROUND KNOWLEDGE IN THE ART PRIOR TO MARCH 10, 2000	21
VIII. DETAILED EXPLANATION OF GROUNDS FOR UNPATENTABILITY	25
A. [Ground 1] Claims 1, 2, 4, 6-11, 25-28, 32-35, 39 and 40 Are Obvious Under 35 U.S.C. § 103 Over Ashworth, Villhauer, Raag and Hanessian.....	25
1. Skilled Workers Were Motivated to Make Better DP-IV Inhibitors	26
2. Ashworth Identified a Lead Compound.....	27
3. Villhauer Identified a Large Adamantyl Group to Modify DP-IV Inhibitors	29
4. Raag Describes a Hydroxylated Adamantane Metabolite	30
5. Hanessian Describes Cyclopropyl Modification to the Proline Moiety.....	31

6.	The Compound of Claim 25 of the '186 Patent Was Obvious Over the Combined Teachings of the References	34
7.	Claims 26-28	38
8.	Genus Claims 1, 2, 4, 6 and 8-11 Are Obvious As Encompassing The Compound Species of Claim 25.....	39
9.	Claims 32-35, 39 and 40: methods of treating type II diabetes mellitus.....	48
B.	[Ground 2] Claims 12-16, 29, 30, 36, 37, 41 and 42 Are Obvious Under §103 Over Ashworth, Villhauer, Raag, Hanessian, Bachovchin and the GLUCOPHAGE Label.....	51
1.	GLUCOPHAGE/ Metformin	51
a.	Weight ratios	53
C.	[Ground 3] Claims 12, 17, 18 and 22 Are Obvious Under §103 Over Ashworth, Villhauer, Raag, Hanessian, Bachovchin and the XENICAL Label	55
D.	[Ground 4] Claims 12 and 19-21 Are Obvious Under §103 Over Ashworth, Villhauer, Raag, Hanessian, Bachovchin and the MEVACOR Label.....	59
1.	MEVACOR/Lovastatin.....	59
a.	Weight ratios	60
IX.	CONCLUSION.....	63
	CERTIFICATE OF COMPLIANCE.....	64

PETITIONER'S EXHIBIT LIST

Exhibit No.	Description
1001	U.S. Reissue Patent 44,186 E to Robl et al. (reissued Apr. 30, 2013)
1002	U.S. Patent No. 6,395,767 to Robl et al. (issued May 28, 2002)
1003	Declaration of David P. Rotella, Ph.D.
1004	Curriculum Vitae of David P. Rotella, Ph.D.
1005	File History of U.S. Patent No. 6,395,767 to Robl et al.
1006	File History of U.S. Reissued Patent 44,186 E to Robl et al.
1007	Doreen M. Ashworth et al., <i>2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV</i> , 6 BIOORG. & MED. CHEM. LTRS. 1163 (1996)
1008	WO Patent App. Pub. No. 98/19998 to Villhauer (pub'd May 14, 1998)
1009	Reetta Raag & Thomas L. Poulos, <i>Crystal Structure of Cytochrome P-450CAM Complexed with Camphane, Thiocamphor, and Adamantane: Factors Controlling P-450 Substrate Hydroxylation</i> , 30 BIOCHEMISTRY 2674 (1991)
1010	Stephen Hanessian et al., <i>The Synthesis of Enantiopure ω-Methanoprolines and ω-Methanopipecolic Acids by a Novel Cyclopropanation Reaction: The "Flattening" of Proline</i> , 36 ANGEW. CHEM. ED. ENGL. 1881 (1997)
1011	WO Patent App. Pub. No. 99/38501 to Bachovchin et al. (pub'd Aug. 5, 1999)
1012	GLUCOPHAGE Label (available by FOIA Jan. 8, 1998)
1013	XENICAL Label (available by FOIA Aug. 9, 1999)
1014	MEVACOR Label (available by FOIA Sept. 15, 1994)
1015	Jian Lin et al., <i>Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics</i> , 95 PROC. NATL. ACAD. SCI. USA 14020 (1998)
1016	Howard E. Hoffman et al., <i>Pharmacokinetics and Metabolism of Rimantadine Hydrochloride in Mice and Dogs</i> , 32(11) ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1699 (1988)
1017	Christopher A. Lipinski et al., <i>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</i> , 23 ADV. DRUG DELIV.

Exhibit No.	Description
	REV. 3 (1996)
1018	Hansch et al., <i>Cluster Analysis and the Design of Congener Sets, in SUBSTITUENT CONSTANTS FOR CORRELATION ANALYSIS IN CHEMISTRY AND BIOLOGY</i> 48 (John Wiley & Sons 1979)
1019	Lindley A. Cates, <i>Calculation of Drug Solubilities by Pharmacy Students</i> , 45 Am. J. Pharm. Educ. 11 (1981)
1020	Walter A. Korfmacher et al., <i>HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process</i> , 2 Drug Disc. Today 532 (1997)
1021	C. Y. Chiou et al., <i>The Cholinergic Effects and Rates of Hydrolysis of Conformationally Rigid Analogs of Acetylcholine</i> , 166 J. Pharm. Exp. Ther. 243 (1969)
1022	Daniel E. Koshland, Jr., <i>The Key-Lock Theory and the Induced Fit Theory</i> , 33 ANGEW. CHEM. ED. ENGL. 2375 (1994)
1023	E.J. Ariëns & A. M. Simonis, <i>Optimalization of Pharmacokinetics – An Essential Aspect of Drug Development – by Metabolic Stabilization</i> , <i>Pharmacochem. Lib.</i> , in 4 PHARMACOCHEM. LIB. 165 (1982)
1024	R. Scott Obach, <i>Prediction of Human Clearance of Twenty-nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-life Approach and Nonspecific Binding to Microsomes</i> , 27 DRUG METAB. DISPOS. 1350 (1999)
1025	Yung-chi Cheng & William H. Prusoff, <i>Relationship Between the Inhibition Constant (KI) and the Concentration of Inhibitor which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction</i> , 22 Biochem. Pharmacol. 3099 (1973)
1026	Debnath Pal & Pinak Chakrabarti, <i>Cis Peptide Bonds in Proteins: Residues Involved, their Conformations, Interactions and Location</i> , 294 J. of Mol. Biol. 271 (1999)
1027	US Provisional Patent Application No. 60/1888,555 to Robl

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.